PH12020551580A1 - Piperidine compounds as covalent menin inhibitor-0s - Google Patents
Piperidine compounds as covalent menin inhibitor-0sInfo
- Publication number
- PH12020551580A1 PH12020551580A1 PH12020551580A PH12020551580A PH12020551580A1 PH 12020551580 A1 PH12020551580 A1 PH 12020551580A1 PH 12020551580 A PH12020551580 A PH 12020551580A PH 12020551580 A PH12020551580 A PH 12020551580A PH 12020551580 A1 PH12020551580 A1 PH 12020551580A1
- Authority
- PH
- Philippines
- Prior art keywords
- covalent
- piperidine compounds
- menin inhibitor
- menin
- formula
- Prior art date
Links
- 102100030550 Menin Human genes 0.000 title abstract 2
- 101710169972 Menin Proteins 0.000 title abstract 2
- 150000003053 piperidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650777P | 2018-03-30 | 2018-03-30 | |
| US201862740549P | 2018-10-03 | 2018-10-03 | |
| PCT/US2019/024729 WO2019191526A1 (en) | 2018-03-30 | 2019-03-29 | Piperidine compounds as covalent menin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12020551580A1 true PH12020551580A1 (en) | 2021-09-13 |
Family
ID=68060814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12020551580A PH12020551580A1 (en) | 2018-03-30 | 2020-09-28 | Piperidine compounds as covalent menin inhibitor-0s |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210115018A1 (https=) |
| EP (1) | EP3774731A4 (https=) |
| JP (1) | JP2021519785A (https=) |
| KR (1) | KR20200136958A (https=) |
| CN (1) | CN111936465A (https=) |
| AU (1) | AU2019243587A1 (https=) |
| BR (1) | BR112020020059A2 (https=) |
| CA (1) | CA3093454A1 (https=) |
| IL (1) | IL277659A (https=) |
| MX (1) | MX2020010181A (https=) |
| PH (1) | PH12020551580A1 (https=) |
| SG (1) | SG11202009543VA (https=) |
| TW (1) | TW202003465A (https=) |
| WO (1) | WO2019191526A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3805215A1 (en) | 2016-06-10 | 2021-04-14 | Vitae Pharmaceuticals, LLC | Inhibitors of the menin-mll interaction |
| WO2019075386A1 (en) | 2017-10-13 | 2019-04-18 | The Regents Of The University Of California | MODULATORS OF MTORC1 |
| BR112021006273A2 (pt) * | 2018-10-03 | 2021-07-06 | Agios Pharmaceuticals Inc | inibidores de menin de pequenas moléculas |
| TW202126636A (zh) | 2019-09-30 | 2021-07-16 | 美商阿吉歐斯製藥公司 | 作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物 |
| MX2022012471A (es) | 2020-04-07 | 2022-11-30 | Syndax Pharmaceuticals Inc | Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas. |
| WO2021207310A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
| TW202204333A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
| TW202311262A (zh) | 2021-05-14 | 2023-03-16 | 美商錫達斯醫藥股份有限公司 | Menin-mll交互作用之抑制劑 |
| WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| WO2025106862A1 (en) * | 2023-11-17 | 2025-05-22 | Kura Oncology, Inc. | Methods of treating kit positive cancers with a menin inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4767842B2 (ja) * | 2003-04-01 | 2011-09-07 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物 |
| US9212180B2 (en) * | 2013-06-12 | 2015-12-15 | The Regents Of The University Of Michigan | Menin-MLL inhibitors and methods of use thereof |
| WO2017192543A1 (en) * | 2016-05-02 | 2017-11-09 | Regents Of The University Of Michigan | Piperidines as menin inhibitors |
| WO2018106818A1 (en) * | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| CA3058448A1 (en) * | 2017-03-31 | 2018-10-04 | The Regents Of The University Of Michigan | Piperidines as covalent menin inhibitors |
-
2019
- 2019-03-29 JP JP2020552868A patent/JP2021519785A/ja active Pending
- 2019-03-29 CA CA3093454A patent/CA3093454A1/en active Pending
- 2019-03-29 MX MX2020010181A patent/MX2020010181A/es unknown
- 2019-03-29 US US17/040,159 patent/US20210115018A1/en not_active Abandoned
- 2019-03-29 BR BR112020020059-0A patent/BR112020020059A2/pt not_active Application Discontinuation
- 2019-03-29 AU AU2019243587A patent/AU2019243587A1/en not_active Abandoned
- 2019-03-29 TW TW108111416A patent/TW202003465A/zh unknown
- 2019-03-29 KR KR1020207030633A patent/KR20200136958A/ko not_active Ceased
- 2019-03-29 CN CN201980023575.6A patent/CN111936465A/zh active Pending
- 2019-03-29 WO PCT/US2019/024729 patent/WO2019191526A1/en not_active Ceased
- 2019-03-29 SG SG11202009543VA patent/SG11202009543VA/en unknown
- 2019-03-29 EP EP19777864.0A patent/EP3774731A4/en not_active Withdrawn
-
2020
- 2020-09-28 PH PH12020551580A patent/PH12020551580A1/en unknown
- 2020-09-29 IL IL277659A patent/IL277659A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021519785A (ja) | 2021-08-12 |
| US20210115018A1 (en) | 2021-04-22 |
| TW202003465A (zh) | 2020-01-16 |
| SG11202009543VA (en) | 2020-10-29 |
| EP3774731A4 (en) | 2021-11-24 |
| MX2020010181A (es) | 2021-01-15 |
| WO2019191526A1 (en) | 2019-10-03 |
| CN111936465A (zh) | 2020-11-13 |
| KR20200136958A (ko) | 2020-12-08 |
| CA3093454A1 (en) | 2019-10-03 |
| IL277659A (en) | 2020-11-30 |
| EP3774731A1 (en) | 2021-02-17 |
| BR112020020059A2 (pt) | 2021-03-30 |
| AU2019243587A1 (en) | 2020-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551580A1 (en) | Piperidine compounds as covalent menin inhibitor-0s | |
| PH12019502263A1 (en) | Piperidines as covalent menin inhibitors | |
| MX384087B (es) | Piperidinas como inhibidores de menina. | |
| PH12020551464A1 (en) | Cd73 inhibitors | |
| WO2017176957A8 (en) | Mdm2 protein degraders | |
| MX2022000376A (es) | Aminopirimidinas como inhibidores de alk. | |
| JOP20210105A1 (ar) | مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp | |
| PH12021550296A1 (en) | Substituted indoles and methods of use thereof | |
| MY196729A (en) | Novel compounds | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| MX371167B (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta). | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| TR201903322T4 (tr) | Kinaz inhibisyonu için heteroaril bileşikleri. | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| GEAP202415883A (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| PH12021550374A1 (en) | Small molecule menin inhibitors | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| ZA202307945B (en) | Pyridopyrimidinone derivative, preparation method therefor, and use thereof | |
| PH12020552261A1 (en) | Proteasome activity enhancing compounds | |
| PH12022551241A1 (en) | Egfr inhibitors | |
| SA522432710B1 (ar) | مركبات حلقية غير متجانسة على هيئة مثبطات نازع تشبّع دلتا-5 وطرق لاستخدامها | |
| PH12021550406A1 (en) | Fused ring derivative used as fgfr4 inhibitor | |
| PH12018501132A1 (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
| MX2022006370A (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso. | |
| MX2019012640A (es) | Metodos de uso de derivados de benzotriazoles trisustituidos como inhibidores de dihidroorotato-oxigenasa. |